Hutchison China Meditech Limited Exercise of Share Options (5202Q)

TIDMHCM

RNS Number : 5202Q

Hutchison China Meditech Limited

30 November 2016

Exercise of Share Options by a Person Discharging Managerial Responsibilities

London: Wednesday, November 30, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Responsibilities), has exercised 25,535 share options (granted in 2007 and which are soon due to expire in May 2017) over ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an exercise price of GBP1.535 per share on November 25, 2016. Such Ordinary Shares will be held in the form of American Depositary Shares ("ADSs") each representing one half of one Ordinary Share.

Following the above exercise of options and subject to the completion of allotment, the holding of Dr Su is 25,535 Ordinary Shares, representing approximately 0.04% of the current issued share capital of Chi-Med, which he intends to hold as a long term investment. Additionally Dr Su holds a further 300,000 unexercised options which would represent a further 0.49% of the issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1     Details of the person discharging managerial responsibilities/person closely associated 
----  ---------------------------------------------------------------------------------------------------------------- 
  a)    Name                                                     Dr Weiguo Su 
----  -------------------------------------------------------  ------------------------------------------------------- 
 2     Reason for the notification 
----  ---------------------------------------------------------------------------------------------------------------- 
  a)    Position/status                                          Executive Vice President and Chief Scientific Officer 
                                                                 of Chi-Med 
----  -------------------------------------------------------  ------------------------------------------------------- 
  b)    Initial notification/Amendment                           Initial notification 
----  -------------------------------------------------------  ------------------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
        or auction monitor 
----  ---------------------------------------------------------------------------------------------------------------- 
  a)    Name                                                     Hutchison China MediTech Limited 
----  -------------------------------------------------------  ------------------------------------------------------- 
  b)    LEI                                                      N/A 
----  -------------------------------------------------------  ------------------------------------------------------- 
 4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
        each type of transaction; (iii) each date; and (iv) each place where transactions have been 
        conducted 
----  ---------------------------------------------------------------------------------------------------------------- 
  a)    Description of the financial instrument, type of         Ordinary Shares of US$1.00 each in the form of ADSs 
        instrument                                               each representing one half of one Ordinary 
        Identification code                                      Share of US$1.00 
                                                                 DI ISIN: KYG4672N1016 
                                                                 ADS ISIN: US44842L1035 
----  -------------------------------------------------------  ------------------------------------------------------- 
  b)    Nature of the transaction                                Exercise of share options on November 25, 2016 at a 
                                                                 price of GBP1.535 per share. Such Ordinary 
                                                                 Shares will be held in the form of ADSs. 
----  -------------------------------------------------------  ------------------------------------------------------- 
  c)    Price(s) and volume(s)                                    Price(s)    Volume(s) 
                                                                  ----------  ---------- 
                                                                   GBP1.535     25,535 
                                                                  ----------  ---------- 
----  -------------------------------------------------------  ------------------------------------------------------- 
  d)    Aggregated information                                   Aggregated volume: 25,535 
         -  Aggregated volume                                     Price information: GBP1.535 
         -  Price 
----  -------------------------------------------------------  ------------------------------------------------------- 
  e)    Date of the transaction                                  2016-11-25 
----  -------------------------------------------------------  ------------------------------------------------------- 
  f)    Place of the transaction                                 Outside a trading venue 
----  -------------------------------------------------------  ------------------------------------------------------- 
 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

 
Investor Enquiries 
Christian Hogg, CEO               [phone] 
 
International Media Enquiries 
Anthony Carlisle,                 [phone] (Mobile)   [e-mail] 
 Citigate Dewe Rogerson 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications    [phone] (Mobile)  [e-mail] 
 
Susan Duffy, BMC Communications   [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group        [phone] (Mobile)  [e-mail] 
 
David Dible,                      [phone] (Mobile)   [e-mail] 
 Citigate Dewe Rogerson 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts       [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDBLBXQFFZFBV

(END) Dow Jones Newswires

November 30, 2016 02:51 ET (07:51 GMT)